BRENNEN

Industries / Frontier science / Cell and gene therapy

Making each dose

This work turns a patient's or a donor's cells into a dose that passes its release tests, and gets it back to the patient in time.

5

Milestones achieved, from 2016 to 2025.

2

To watch for: announced, not yet confirmed outside.

2

Open deliverables. Nobody has shipped them.

The road

AchievedWatch forOpen

Achieved

  1. 2016

    Automated CAR-T in one machine

    A University College London team ran the whole CAR-T process (cell selection, activation, adding the gene with a lentivirus, and growth) inside Miltenyi Biotec's CliniMACS Prodigy, a machine that keeps cells in a closed, single-use tubing set and feeds them automatically. Using blood from healthy volunteers, the cells matched hand-made batches for gene transfer, cell type and killing, and the yield was enough for expected doses.

    Lessona closed machine lets a hospital without a large clean-room team make cells, which the authors said had been limited to a few centres.

    europepmc.org

    Credit

    Ulrike Mock, Martin Pule, Adrian Thrasher, Waseem Qasim and colleagues (University College London), with Miltenyi Biotec staff

  2. 2018

    Doses outside the label

    In July 2018, two months after Kymriah's US approval for diffuse large B-cell lymphoma, Novartis said some doses made for those patients were not meeting their commercial specifications, the release tests set at approval. The FDA had required at least 80% of the T cells in a dose to be alive, against the 70% Novartis aimed for in its trials. Novartis gave such doses free through an expanded-access programme. In December 2019 BioPharma Dive reported that about 10% of the time Novartis could not ship a dose at all, and that real-world data presented at the American Society of Hematology meeting found that 29 of 102 lymphoma patients and 14 of 92 leukaemia patients had received doses below 80%, with no sign that they fared worse.

    Lessonrelease limits fixed at approval decide which doses can be sold, so they need data linking them to how patients do.

    pharmtech.combiopharmadive.com

    Credit

    Novartis; FDA

  3. 2022

    Too few manufacturing slots

    After the first CAR-T for multiple myeloma, ide-cel, was approved in March 2021, the makers of the two myeloma CAR-T products gave each centre a small number of production slots a month. A Mayo Clinic doctor said the makers blamed a lack of commercial-grade viral vector, the disabled virus that carries the CAR gene. At the University of Kansas, 40 patients were eligible from March to July 2021; 24 got a slot and 16 did not. Median survival was 9 months for those who did not; it was not reached for those who did. A Moffitt Cancer Center doctor said in 2022 that its waiting list was at times over 100 patients.

    Lessonmaking capacity and vector supply, not only the medicine, decided who was treated.

    frontiersin.orgascopost.com

    Credit

    Nausheen Ahmed, Leyla Shune and colleagues (University of Kansas Cancer Center); The ASCO Post

  4. 2025

    Platform status granted, then revoked

    In June 2025 the FDA gave its first platform technology designation to Sarepta's AAVrh74 viral carrier. The designation lets a company reuse data from an approved product that shares the same well-understood, reproducible technology, to speed review and manufacturing checks for the next one. On 18 July 2025 the FDA revoked it after three deaths that appeared to result from acute liver failure in people given therapies built on that carrier, saying the evidence no longer showed it could be used in more than one drug without harming safety.

    Lessona shared platform shares its risks as well as its data.

    aabb.orgfda.gov

    Credit

    FDA; Sarepta Therapeutics

  5. 2025

    Point-of-care manufacturing becomes law

    On 23 July 2025 UK rules came into force that let medicines be made where the patient is treated, such as a hospital, under a new manufacturer's licence. One licensed control site supervises many places of manufacture, each working to a written master file. The UK government calls it a world first, and says a cancer patient's immune cells could be collected, changed and returned within days.

    gov.ukgov.uk

    Credit

    Medicines and Healthcare products Regulatory Agency (MHRA); UK Department of Health and Social Care

Watch for

  1. CAR-T made in two days

    Novartis says its T-Charge process makes a CD19 CAR-T, rapcabtagene autoleucel, in under two days, against the longer growth periods of earlier products, and that this keeps more naive and stem-like T cells, the kind that multiply and persist best. In its early lymphoma trial, doses 25 times lower than Kymriah gave response rates of 75% and 80%. An October 2025 conference abstract from a lupus study of 21 patients still described it as rapidly made. Novartis paused its autoimmune trials of the product in August 2026 after three deaths; two cancer trials continue.

    Achieved whena regulator approves a CAR-T made in under two days, or an outside group reports the same making time and cell quality.

    europepmc.orgacrabstracts.orghealio.com

    Claimed by

    Novartis, September 2023, restated October 2025

  2. Plant for donor iPS cells

    Sumitomo Pharma says its SMaRT plant in Suita, Osaka, is the world's first commercial-scale plant for medicines made from donor iPS cells, and that its partner S-RACMO will make Amchepry for Parkinson's disease there, from cell stock supplied by the CiRA Foundation.

    Achieved whenthe plant supplies doses for routine use and a regulator's inspection or an outside report confirms it.

    sumitomo-pharma.com

    Claimed by

    Sumitomo Pharma and RACTHERA, March 2026

Open

  1. 01

    A public vein-to-vein table

    A free table of vein-to-vein time, the days from collecting a patient's cells to infusing the finished dose, for every approved CAR-T and T-cell product. Each row gives product, disease, country, year, the median reported, the exact definition the source used, and a link.

    The brief
    Credit · unclaimed
  2. 02

    A table of failed doses

    A free table, one row per published report, of how often making a CAR-T or other T-cell dose failed or gave a dose outside its release limits: product, disease, country, years, number of patients, number of failures, the reasons given (such as poor growth, low viability or low purity) and what happened next (remade, given anyway or not given). Every figure is a count taken from a paper, label or conference abstract, with its source.

    The brief
    Credit · unclaimed

Open 01 · the brief

A public vein-to-vein table

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A free table of vein-to-vein time, the days from collecting a patient's cells to infusing the finished dose, for every approved CAR-T and T-cell product. Each row gives product, disease, country, year, the median reported, the exact definition the source used, and a link.

Why it is still open

A 2025 review and meta-analysis by Locke and colleagues compared three products in one lymphoma, large B-cell lymphoma (medians of 30.6 days for axi-cel, 35.9 for liso-cel and 48.4 for tisa-cel), and found that in patients given axi-cel, waits of 40 days or more went with fewer complete responses. A Kansas study reported 42 days for a myeloma product in 2021. A Europe PMC search of paper titles for "vein-to-vein" found six papers, none a table across all products and countries.

europepmc.orgfrontiersin.org

Built with what exists

The Europe PMC and ClinicalTrials.gov APIs; FDA and EMA product documents read with pdftotext; a large language model such as Claude to find candidate figures, with a person confirming each one; a CSV in a public repository.

  1. First step

    Enter the figures from the 2025 meta-analysis and the Kansas study into a CSV, with each source's definition of the start and end points.

  2. Done looks like

    Every FDA-approved CAR-T and T-cell product has at least one sourced vein-to-vein figure or is marked "not reported", and a second person's check of 30 random figures finds at least 95% match their sources.

Open 02 · the brief

A table of failed doses

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A free table, one row per published report, of how often making a CAR-T or other T-cell dose failed or gave a dose outside its release limits: product, disease, country, years, number of patients, number of failures, the reasons given (such as poor growth, low viability or low purity) and what happened next (remade, given anyway or not given). Every figure is a count taken from a paper, label or conference abstract, with its source.

Why it is still open

Reports come one country or one survey at a time. The UK National CAR T Panel found manufacturing failure in 38 of 981 patients (3.87%) approved for CAR-T for large B-cell lymphoma. The EBMT, the European society for blood and marrow transplantation, surveyed its centres on failures and out-of-specification doses in 2025. No table across products and countries turned up in searches.

repository.cam.ac.ukresearchinformation.umcutrecht.nl

Built with what exists

The Europe PMC API; FDA labels and review documents read with pdftotext; a large language model such as Claude to find candidate figures and quote the sentence each came from, with a person confirming each one; a CSV file in a public GitHub repository.

  1. First step

    Search Europe PMC titles and abstracts for "manufacturing failure" with "CAR T", and enter the first ten reports with each one's definition of failure.

  2. Done looks like

    Every FDA-approved CAR-T product has at least one sourced failure figure or is marked "not reported", the UK panel's 38 of 981 is reproduced from its paper, and a second person's check of 30 random figures finds at least 95% match their sources.